Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the pri...
Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target ...
Oppenheimer analyst Matthew Biegler downgrades Cartesian Therapeutics (NASDAQ:RNAC) from Outperform to Peer Perform.
Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant i...
Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of 3,563,247 shares of its comm...
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 ob...
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
Oppenheimer analyst Matthew Biegler reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $50 pric...
